- Sarepta Therapeutics | Biopharmaceutical Company for Rare Diseases
We are focused on the development of precision genetic medicines to treat rare neuromuscular and central nervous system diseases Learn more about Sarepta
- News Press Releases | Sarepta Therapeutics
Read news and articles from Sarepta, a global biotechnology company developing potentially life-changing precision genetic medicine
- Our Pipeline | Sarepta Therapeutics
Sarepta’s industry leading pipeline is comprised of over 40 programs in various stages of development across 3 technologies, RNA, gene therapy and gene editing, and multiple therapeutic areas including neuromuscular, CNS and cardiology
- Sarepta Therapeutics Announces Strategic Restructuring and Pipeline . . .
– After strategic review, Sarepta focuses pipeline on high-impact programs, prioritizing potentially best-in-class siRNA platform assets – Strategic restructuring includes reduced operating expenses, delivering approximately $400 million in anticipated annual cost savings, and implementing a 36%
- About Our Company | Sarepta Therapeutics
Sarepta is a global biotechnology company on an urgent mission: to engineer precision genetic medicine for rare diseases that devastate lives and cut futures short
- Investor Relations | Sarepta Therapeutics, Inc.
The Investor Relations website contains information about Sarepta Therapeutics, Inc 's business for stockholders, potential investors, and financial analysts
- Our Disease Areas | Sarepta Therapeutics
At Sarepta, we’re committed to pursuing some of the world’s most debilitating, prevalent, and complex rare genetic diseases Learn more about the disease areas we're focused on
- Sarepta Therapeutics Announces First Quarter 2025 Financial Results and . . .
In order to provide Sarepta’s investors with an understanding of its current results and future prospects, this press release contains statements that are forward-looking
|